Five-year survival on infliximab in rheumatoid arthritis patients: analysis from an Italian registry (GISEA) by different calendar years

Elisa Gremese, Florenzo Iannone, Fausto Salaffi, Antonio Marchesoni, Roberto Gorla, Fabiola Atzeni, Marcello Govoni, Giovanni Lapadula, E. G. Favalli, C. Bazzani, P. Sarzi-Puttini, S. Lopriore, C. Caimmi

Risultato della ricerca: Contributo in rivistaArticolo in rivista

3 Citazioni (Scopus)

Abstract

To assess long-term drug survival and effectiveness in biological drug-naïve patients with rheumatoid arthritis (RA), starting infliximab as first treatment, in the period 2000-2009, comparing different calendar years.
Lingua originaleEnglish
pagine (da-a)524-530
Numero di pagine7
RivistaCLINICAL AND EXPERIMENTAL RHEUMATOLOGY
Volume33
Stato di pubblicazionePubblicato - 2015

Keywords

  • Adult
  • Aged
  • Antibodies, Monoclonal
  • Antirheumatic Agents
  • Arthralgia
  • Arthritis, Rheumatoid
  • C-Reactive Protein
  • Demography
  • Disability Evaluation
  • Female
  • Humans
  • Infliximab
  • Italy
  • Kaplan-Meier Estimate
  • Male
  • Middle Aged
  • Pain Measurement
  • Patient Acuity
  • Patient Outcome Assessment
  • Registries
  • Remission Induction
  • Rheumatoid Factor
  • Time-to-Treatment

Fingerprint Entra nei temi di ricerca di 'Five-year survival on infliximab in rheumatoid arthritis patients: analysis from an Italian registry (GISEA) by different calendar years'. Insieme formano una fingerprint unica.

Cita questo